Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-K10 in Moderate-to-Severe Atopic Dermatitis
NCT07479615Phase 3Not yet recruiting
- Sponsor
- Hunan Mabgeek Biotechnology
- Start
- May 2026
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of comekibart in atopic dermatitis (AD), sponsored by Hunan Mabgeek Biotechnology. Planned start May 2026; status: not yet recruiting.
02
Drugs
comekibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07479615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479615.